Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
NVCT
NVCT
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
NVCT News
Nuvectis Pharma Prices 5 Million Share Offering at $20 Each
Jun 30 2026
NASDAQ.COM
Nuvectis Pharma Prices Public Offering at $20 per Share
Jun 30 2026
seekingalpha
Nuvectis Pharma Prices $100 Million Public Offering
Jun 30 2026
Newsfilter
Nuvectis Pharma Launches Underwritten Public Offering
Jun 29 2026
seekingalpha
Pulsenmore Soars 280% on Ouma Health Collaboration
Jun 25 2026
NASDAQ.COM
Tenon Files S-1, Stock Surges 77.57%
Jun 23 2026
NASDAQ.COM
Nuvectis Expands Clinical Development Pipeline with New Licensing Agreements
Jun 22 2026
Newsfilter
Multiple Companies Show Strong Stock Performance
Jun 20 2026
NASDAQ.COM
Nuvectis Pharma to Present at BioConnect Investor Conference
May 14 2026
Newsfilter
Nuvectis Pharma Reports Q1 2026 Financial Results and NXP900 Update
May 05 2026
Newsfilter
NUVECTIS PHARMA, INC. ANNOUNCES FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS FOR FIRST QUARTER 2026
May 05 2026
moomoo
Nuvectis Pharma Reports FY GAAP EPS of -$1.32
Feb 11 2026
seekingalpha
Nuvectis Pharma Reports 2025 Financial Results and Business Progress
Feb 11 2026
Newsfilter
Nuvectis Initiates Phase 1b Study of NXP900 with Osimertinib for EGFRmut+NSCLC
Dec 17 2025
Globenewswire
Nuvectis Initiates Phase 1b Study of NXP900 with Osimertinib for EGFRmut+NSCLC
Dec 17 2025
Newsfilter
Nuvectis Pharma, Inc. Announces Financial Results and Business Highlights for Q3 2025
Nov 04 2025
Newsfilter
Show More News
